Cargando…

GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes

Diabetes mellitus is a chronic disease prevalence of which is high and continually growing. Cardiovascular disease continues to be the leading cause of death in patients with T2DM. The prevention of cardiovascular complications and the cardiovascular safety of treatments should be a primary objectiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	del Olmo-Garcia, María Isabel, Merino-Torres, Juan Francisco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5902002/ https://www.ncbi.nlm.nih.gov/pubmed/29805980 http://dx.doi.org/10.1155/2018/4020492

Ejemplares similares

Effects of GLP-1 receptor agonists on neurological complications of diabetes
por: García-Casares, Natalia, et al.
Publicado: (2023)

The Cardiovascular Effects of GLP-1 Receptor Agonists
por: Okerson, Theodore, et al.
Publicado: (2012)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
por: Saraiva, Francisco Kerr, et al.
Publicado: (2014)

Cardiovascular safety outcomes of once‐weekly GLP‐1 receptor agonists in people with type 2 diabetes
por: Goldman, Jennifer D.
Publicado: (2020)

GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
por: Górriz, José Luis, et al.
Publicado: (2020)

Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor
por: Helmstädter, Johanna, et al.
Publicado: (2021)

Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK
por: Boye, Kristina S., et al.
Publicado: (2019)

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
por: Nauck, Michael A., et al.
Publicado: (2020)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

Role and development of GLP-1 receptor agonists in the management of diabetes
por: Chia, Chee W, et al.
Publicado: (2009)

Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

GLP-1 Receptor Agonists in Type 2 Diabetes and Beyond – New Insights 2015
por: Gallwitz, Baptist
Publicado: (2015)

Safety and tolerability of once‐weekly GLP‐1 receptor agonists in type 2 diabetes
por: Trujillo, Jennifer
Publicado: (2020)

Treatment of Type 2 Diabetes With GLP-1 Receptor Agonists Among Patients With CKD
por: Østergaard, Jakob A., et al.
Publicado: (2022)

GLP-1 Receptor Agonists and Kidney Protection
por: Greco, Eulalia Valentina, et al.
Publicado: (2019)

The effect of GLP-1 receptor agonist lixisenatide on experimental diabetic retinopathy
por: Oezer, Kuebra, et al.
Publicado: (2023)

Prediction of response to GLP-1 receptor agonist therapy in Japanese patients with type 2 diabetes
por: Imai, Kenjiro, et al.
Publicado: (2014)

The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date
por: Antza, Christina, et al.
Publicado: (2019)

GLP-1 Receptor Agonists for Type 2 Diabetes and Their Role in Primary Care: An Australian Perspective
por: Rasalam, Roy, et al.
Publicado: (2019)

Predictors of Responsiveness to GLP-1 Receptor Agonists in Insulin-Treated Patients with Type 2 Diabetes
por: Gavigan, Colleen, et al.
Publicado: (2023)

GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms
por: Kawanami, Daiji, et al.
Publicado: (2020)

GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Physiology to Clinical Outcomes
por: Rojano Toimil, Alba, et al.
Publicado: (2021)

GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions
por: Yu, Ji Hee, et al.
Publicado: (2022)

Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life
por: Longato, Enrico, et al.
Publicado: (2020)

GLP-1 receptor agonist ameliorates experimental lung fibrosis
por: Fandiño, Juan, et al.
Publicado: (2020)

Effects of GLP‐1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and meta‐analysis
por: Kelly, Michael, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus
por: Capel, Margarita, et al.
Publicado: (2019)

Free Versus Fixed-Ratio Combination of Basal Insulin and GLP-1 Receptor Agonists in Type 2 Diabetes Uncontrolled With GLP-1 Receptor Agonists: A Systematic Review and Indirect Treatment Comparison
por: Jung, Han Na, et al.
Publicado: (2022)

An overview of GLP-1 agonists and recent cardiovascular outcomes trials
por: Sheahan, Kelsey H, et al.
Publicado: (2020)

GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art
por: Granata, Antonio, et al.
Publicado: (2022)

FRI652 Type 2 Diabetes Management: More GLP1 Agonists And Less Metformin?
por: Lopez Maldonado, Francisco J, et al.
Publicado: (2023)

Purslane Effect on GLP-1 and GLP-1 receptor in type 2 diabetes
por: Heidarzadeh, Sara, et al.
Publicado: (2013)

Designing and computational analyzing of chimeric long-lasting GLP-1 receptor agonists for type 2 diabetes
por: Ehsasatvatan, Maryam, et al.
Publicado: (2023)

Type 2 Diabetes risk alleles in Peptidyl-glycine Alpha-amidating Monooxygenase influence GLP-1 levels and response to GLP-1 Receptor Agonists
por: Umapathysivam, Mahesh M, et al.
Publicado: (2023)

Basal Insulin Use With GLP-1 Receptor Agonists
por: Anderson, Sarah L., et al.
Publicado: (2016)

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
por: Zhao, Xin, et al.
Publicado: (2021)

GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs
por: Giugliano, Dario, et al.
Publicado: (2021)

Novel GLP-1 Fusion Chimera as Potent Long Acting GLP-1 Receptor Agonist
por: Wang, Qinghua, et al.
Publicado: (2010)

GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease
por: Lee, Jinmi, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_us85bvo8obrv0pvnf10esu9trf